A single-centre Phase Ib multiple ascending dose clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of IW 2143 (BNC 210) in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2016
At a glance
- Drugs BNC 210 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Adverse reactions
- 20 Sep 2016 Results presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
- 16 Sep 2015 Status changed from not yet recruiting to completed.
- 16 Sep 2015 Positive results published in a Bionomics media Release.